|Home | About | Journals | Submit | Contact Us | Français|
Transcatheter, intramyocardial injections of bone marrow derived cell therapy produces reverse remodeling in large animal models of ischemic cardiomyopathy.
We used cardiac magnetic resonance imaging (CMR) in patients with LV dysfunction related to remote myocardial infarction (MI) to test the hypothesis that bone marrow progenitor cell injection cause functional recovery of scarred myocardium and reverse remodeling.
Eight patients (age 57.2±13.3) received transendocardial, intramyocardial injection of autologous bone marrow progenitor cells (mononuclear or mesenchymal stem cells) in LV scar and border zone. All patients tolerated the procedure with no serious adverse events. CMR at 1-year demonstrated a decrease in end-diastolic volume (208.7±20.4 vs. 167.4±7.32mL; p=0.03), a trend towards decreased end-systolic volume (142.4±16.5 vs. 107.6±7.4mL; p=0.06), decreased infarct size (p<0.05), and improved regional LV function by peak Ecc in the treated infarct zone (-8.1±1.0 vs. -11.4±1.3; p=0.04). Improvements in regional function were evident at 3 months, while the changes in chamber dimensions were not significant until 6 months. Improved regional function in the infarct zone strongly correlated with reduction of EDV (r2=0.69, p=0.04) and ESV (r2=0.83, p=0.01).
These data suggest that transcatheter, intramyocardial injections of autologous bone marrow progenitor cells improve regional contractility of a chronic myocardial scar and these changes predict subsequent reverse remodeling. The findings support the potential clinical benefits of this new treatment strategy and ongoing randomized clinical trials.
In a series of detailed preclinical porcine studies, we have demonstrated that transcatheter, intramyocardial injection of bone marrow derived progenitor cells to chronically scarred myocardium is safe and improves left ventricular (LV) regional function, reduces scar size, and creates reverse remodeling1. A therapy that leads to reverse remodeling in chronically scarred human hearts would be precedent setting, and predicted to have favorable clinical benefits for patients. Using various imaging modalities, a growing number of clinical trials of intramyocardial bone marrow cell injections in patients with chronic ischemic heart failure have shown improved regional function; however, these improvements in regional contractility have only translated to modest global functional changes.2,3 Furthermore, the relationship of improved regional contractility and reverse remodeling has not been investigated. Here we tested the hypothesis that intramyocardial injection of bone marrow derived stem cells into humans with chronically scarred myocardium causes functional restoration followed by reverse remodeling. The data here derive from the phase I pilot of the Transendocardial Autologous Cells in Ischemic Heart Failure (TAC-HFT, clinicaltrials.gov identifier NCT00768066) study of catheter-based intramyocardial injections of autologous bone marrow progenitor cells in patients with LV dysfunction secondary to remote myocardial infarction.4
Eight patients with a diagnosis of ischemic cardiomyopathy underwent bone marrow aspiration from the iliac crest followed by transendocardial injection (Helical Infusion Catheter; BioCardia, San Carlos, CA) of autologous bone marrow progenitor cells (mononuclear cells, n=4 or mesenchymal stem cells, n=4). Cardiac magnetic resonance imaging (CMR) phenotyping of structure and function was conducted at baseline, 3 and 6 months, and 1 year after cell therapy. Written informed consent was obtained from all patients on this Institutional Review Board approved protocol. Online Supplement contains detailed methods.
Eight patients [age 57.2±13.3 years, all male with remote MI (68.8±21.4 months, range 4 months to 11 years)] underwent transendocardial injection of bone marrow progenitor cells. No patient experienced a serious adverse event (Online Supplement).
Cine CMR demonstrated a decrease in EDV (p=0.033) and a trend towards decreased ESV (p=0.058) (Figure 1, Online Figure II). Reductions in chamber volumes were significant at 6 and 12 months compared to baseline for ESV (p=0.022 and p=0.023, respectively) and EDV (p=0.009 and p=0.014, respectively). EF and LV mass did not change (p=NS). A strong correlation between the changes in EDV and ESV (r2=0.87, p=0.002) demonstrates parallel decreases in chamber volumes. MI size evaluated by delayed myocardial hyper-enhancement decreased by 18.3±8.3% (p<0.05; Fig 1D and Online Figure I).
Peak eulerian circumferential strain (Ecc), a measure of regional contractility calculated from tagged CMR images, showed improved regional function of the infarct zone (IZ) (p=0.039) that restored function to the level of the borderzone (Figure 1 & 2). The IZ improvements were evident as early as 3 months and persisted at 6 and 12 months compared to baseline (p=0.02, p=0.013, and p=0.029, respectively), and strongly correlated with the changes in EDV (r2=0.69, p=0.04) and ESV (r2=0.83, p=0.01) (Figure 2). Regional function in border and remote zones did not change (p=NS).
Here we show that transcatheter, intramyocardial injection of autologous bone marrow preparations in patients with chronic ischemic cardiomyopathy is well tolerated and produces functional recovery in scarred myocardium and reverse remodeling of the LV chamber. Importantly, the functional recovery is evident at 3 months following injection, and precedes reverse remodeling. As all patients had documented MI and were previously revascularized, these findings support myocardial regeneration and mirror the phenotype observed in porcine models of chronic ischemic cardiomyopathy.1,5
The present findings have several major implications. First, we have established that bone marrow derived cell therapy clearly can enable reverse remodeling of dilated hearts, a phenotypic change that would be expected to have positive clinical implications. Second, the reverse remodeling caused substantial parallel declines in systolic and diastolic volumes, so that an EF increase was obscured; accordingly, this strongly suggests that EF is not a good primary endpoint for assessing responses to cell therapy in dilated hearts and that chamber size, MI size, or regional function are more likely to reflect a favorable outcome. Finally, these data strongly indicate that a high-resolution imaging tool such as MRI, capable of detecting the latter outcomes, is necessary for trials of cardiac regeneration.
While there is enormous enthusiasm for the possibility of repair of ischemic cardiomyopathy with cell-based therapy, mechanisms and manifestations of this strategy remain highly controversial. To address this, we phenotyped patients using cardiac MRI, which is recognized as the “reference standard” for quantitative assessment of LV function and has been shown to be the most accurate and reproducible imaging modality to assess global and regional LV function.6,7 Regional functional improvements (peak Ecc) of the infarct territory were calculated by harmonic phase MRI, arguably the most accurate non-invasive analytical imaging modality to measure regional strain8,9
The early improvements in regional contractility of a treated infarct predicted later reverse remodeling. Regional strain of the infarct territory improved as early as 3 months following cell injection, which persisted at 6 months and 1 year (Figure 1). The reduction in chamber volumes was not evident until 6 months and the correlation with improved regional strain was not apparent until 6 months and continued at 1 year (Figure 2). This suggests that the first manifestation of bone marrow cell therapy on the heart is improved regional function that later contributes to reverse remodeling. As a corollary to this finding, infarct size was reduced by 3 months after treatment.
Preclinical studies of bone marrow cell therapy for ischemic heart disease have demonstrated improved EF, but this has not translated to early phase studies in humans. We show a strong parallel decrease in both EDV and ESV (r2=0.87, p=0.002) 12 months after treatment. Indeed this finding strongly suggests that EF may not be a good outcome measure for studies of cell therapy for remodeled ventricles. Importantly, both LV size and infarct size are important clinical indicators of outcome in patients with ischemic cardiomyopathy,10 and the results here highlight a highly adaptive response to cell therapy, even in the absence of a net increase in EF.
This study lacks the power to determine superiority between MSCs or whole bone marrow, and does not have a placebo comparison group. Although, only 4 patients had longitudinal assessment of scar size (due to artifact distortion from delayed enhancement imaging from ICD leads), MI size was reduced in each of these subjects. Each of these limitations will be definitively addressed in the ongoing TAC-HFT and POSEIDON trials, which together will treat 90 patients in placebo-controlled, blinded fashion.
In conclusion, MRI provides a unique opportunity to image the in-vivo structural and functional changes after bone marrow stem cell therapy for the heart. Our data suggest human autologous bone marrow progenitor cells increase regional contractility of injected myocardial scar tissue within 3 months of treatment, and these functional changes are associated with later reverse remodeling. These findings strongly support ongoing clinical investigation of cell-based therapy for cardiomyopathy, and support the use of regional function and chamber size as important endpoints.
What is known?
What new information does this article contribute?
Early clinical trials have shown the capacity of intramyocardial injections of bone marrow derived progenitor cells to improve regional function with modest improvements in ejection fraction (EF). We used cardiac MRI to phenotype the in-vivo changes of the left ventricle following catheter-based intramyocardial injections of bone marrow progenitor cells. We show improved regional function of scarred myocardium within 3 months of therapy and this predicts later reverse remodeling. For the first time, we show that this therapy can improve diastolic volumes and parallel decreases in both end-systolic and end-diastolic volume contribute to the lack of overall improvements in EF.
This study was funded by the University of Miami Interdisciplinary Stem Cell Institute and BioCardia, Inc. Dr. Hare is also funded by NIH grant U54-HL081028.
Authors who are employees of BioCardia, Inc are identified as such. All authors reviewed and approved the analysis and manuscript. The University of Miami supervised the management of the study and EMMES Corporation was responsible for data collection, site monitoring and analyses.